Eilmeldung

AR410 أشخاص في فئة "التهديدات الإسلاموية" في ألمانيا ARآلاف يفرون من حرائق الغابات في فرنسا وإسبانيا ARإيران تحذّر من تصعيد أمريكي جديد وتؤكد جاهزيّتها الكاملة للرد ARالفيفا يفتح إجراءات انضباطية ضد الأرجنتين بسبب انتهاكات في كأس العالم ARأميركا تعفّض على كيانات إيرانية بتهمة ابتزاز السفن في هرمز ARضربات أمريكية سعودية ضد ميليشيات موالية لإيران في العراق ARالنعمان يؤكد عدم السماح بتصرفات فردية أو انتهاكات من خارج العراق ARالهجوم الأوكراني على سفينة إيرانية في بحر قزوين: شبكة إسرائيلية-أوكرانية من أذربيجان ARحرائق أوروبا وتغير المناخ: استثمار في الطاقة المتجددة وحماية الأجيال القادمة ARإيران تستهدف قاعدة جوية وقدرة قيادة أمريكية في الأردن بالصواريخ AR410 أشخاص في فئة "التهديدات الإسلاموية" في ألمانيا ARآلاف يفرون من حرائق الغابات في فرنسا وإسبانيا ARإيران تحذّر من تصعيد أمريكي جديد وتؤكد جاهزيّتها الكاملة للرد ARالفيفا يفتح إجراءات انضباطية ضد الأرجنتين بسبب انتهاكات في كأس العالم ARأميركا تعفّض على كيانات إيرانية بتهمة ابتزاز السفن في هرمز ARضربات أمريكية سعودية ضد ميليشيات موالية لإيران في العراق ARالنعمان يؤكد عدم السماح بتصرفات فردية أو انتهاكات من خارج العراق ARالهجوم الأوكراني على سفينة إيرانية في بحر قزوين: شبكة إسرائيلية-أوكرانية من أذربيجان ARحرائق أوروبا وتغير المناخ: استثمار في الطاقة المتجددة وحماية الأجيال القادمة ARإيران تستهدف قاعدة جوية وقدرة قيادة أمريكية في الأردن بالصواريخ

Wegovy

Stabil39 Meldungen13 QuellenZuletzt aktualisiert: vor 6 Tagen

Verwandte ThemenNovo Nordisk Ozempic weight loss semaglutide Mounjaro obesity diabetes GLP-1

Neueste Meldungen

Australia warns on Ozempic, Mounjaro eye disorder risk

Gesundheit·vor 6 TagenKI-Zusammenfassung

Australia warns on Ozempic, Mounjaro eye disorder risk

Australia's Therapeutic Goods Administration (TGA) has warned about a "rare but severe" eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), linked to type 2 diabetes and obesity treatments like Ozempic and Mounjaro. The warning, based on 36 reported cases, advises patients to seek urgent medical attention for sudden vision loss but not to stop treatment without consulting a doctor.

3 Min. Lesezeit

Regulator Warns of Rare Eye Disorder Risk with GLP-1 Diabetes and Obesity Drugs

Gesundheit·vor 6 TagenKI-Zusammenfassung

Regulator Warns of Rare Eye Disorder Risk with GLP-1 Diabetes and Obesity Drugs

Australia's TGA has issued a safety warning for GLP-1 drugs like Ozempic, Mounjaro, and Wegovy, linking them to non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye disorder causing potential permanent vision loss. Experts advise caution but not panic, stressing consultation with prescribers.

ABC Top Stories

3 Min. Lesezeit

GLP-1 Grubu İlaçların Saç Dökülmesi Riski Ortaya Çıktı

23.7.2026KI-Zusammenfassung

GLP-1 Grubu İlaçların Saç Dökülmesi Riski Ortaya Çıktı

Pennsylvania Üniversitesi araştırmacıları, Ozempic ve Wegovy gibi GLP-1 ilaçlarının saç dökülmesi riskini SGLT-2 ve DPP-4 inhibitörlerine kıyasla daha yüksek buldu. Çalışma, hızlı kilo kaybı ve besin eksikliğinin geçici saç dökülmesine yol açabileceğini belirtiyor.

1 Min. Lesezeit

GLP-1 Drug Implant Aims to Solve Long-Term Weight Loss Maintenance

Gesundheit·11.7.2026KI-Zusammenfassung

GLP-1 Drug Implant Aims to Solve Long-Term Weight Loss Maintenance

Vivani Medical is developing a GLP-1 implant for long-term weight loss maintenance, potentially reducing side effects and injection fatigue. The device, an experimental semaglutide implant, aims for twice-yearly or annual administration, complementing existing GLP-1 treatments. However, it faces clinical trials, regulatory hurdles, and questions about cost and physician adoption.

CNBC US Markets

8 Min. Lesezeit

Zayıflama İğneleri Kalp Ritmine Ek Yük Getiriyor: Yeni Araştırma Sonuçları

Gesundheit·10.7.2026KI-Zusammenfassung

Zayıflama İğneleri Kalp Ritmine Ek Yük Getiriyor: Yeni Araştırma Sonuçları

Giyilebilir teknoloji şirketi WHOOP'un araştırması, zayıflama iğnesi kullananlarda kalp ritminde ek yük ve stres oluştuğunu gösterdi. Haftada 30 dakika egzersiz ve ağırlık antrenmanı bu riskleri azaltıyor.

2 Min. Lesezeit

Ozivy incluído na Lista de Medicamentos de Referência da Anvisa

Gesundheit·10.7.2026KI-Zusammenfassung

Ozivy incluído na Lista de Medicamentos de Referência da Anvisa

Ozivy, fabricado pela EMS, foi incluído na Lista de Medicamentos de Referência da Anvisa. Isso permite que outros laboratórios desenvolvam versões genéricas ou similares do medicamento no futuro, que tem o mesmo princípio ativo do Ozempic.

2 Min. Lesezeit

Novo Nordisk's Wegovy and Ozempic Gain Ground as Indian Generics Slow

Business·9.7.2026KI-Zusammenfassung

Novo Nordisk's Wegovy and Ozempic Gain Ground as Indian Generics Slow

Novo Nordisk's weight-loss drugs Wegovy and Ozempic are seeing steady sales growth in India, outpacing generic versions. This comes as the frenzy for Indian generics wanes amid a crowded market, with innovators maintaining a steadier growth trajectory.

3 Min. Lesezeit

Wegovy Weight-Loss Pill Now Available in UK Pharmacies, Not Yet on NHS

Gesundheit·6.7.2026KI-Zusammenfassung

Wegovy Weight-Loss Pill Now Available in UK Pharmacies, Not Yet on NHS

The once-a-day Wegovy weight-loss pill, containing semaglutide, is now available in UK high street and online pharmacies for private prescription. It is not yet available on the NHS. The pill offers a needle-free alternative to the jab but requires specific administration on an empty stomach.

3 Min. Lesezeit

Wegovy Weight Loss Pill Now Available Privately in UK

Gesundheit·6.7.2026KI-Zusammenfassung

Wegovy Weight Loss Pill Now Available Privately in UK

The once-daily Wegovy weight loss pill, containing semaglutide, is now available privately in the UK, though not yet on the NHS. It works similarly to the injectable version by mimicking a gut hormone to reduce appetite and increase fullness, requiring a BMI of 30+ or 27-30 with weight-related conditions. Strict guidelines apply for taking the pill on an empty stomach, and costs range from £99 to £199 per month.

5 Min. Lesezeit

Governo estuda incluir semaglutida no SUS para tratamento de obesidade

Gesundheit·23.6.2026KI-Zusammenfassung

Governo estuda incluir semaglutida no SUS para tratamento de obesidade

O Ministério da Saúde anunciou um estudo para avaliar o uso da semaglutida no SUS. A substância, usada no tratamento de diabetes e obesidade, pode reduzir o apetite e levar à perda de peso. A proposta visa superar a barreira de preço, com a Novo Nordisk oferecendo um desconto de 59%.

5 Min. Lesezeit

Grupo hacker FulcrumSec alega ter roubado dados da Novo Nordisk e ameaça vender informações

Business·16.6.2026KI-Zusammenfassung

Grupo hacker FulcrumSec alega ter roubado dados da Novo Nordisk e ameaça vender informações

Grupo hacker FulcrumSec alega ter roubado mais de 700 mil arquivos da Novo Nordisk, incluindo dados de pacientes e funcionários, e ameaça vender as informações após não conseguir extorquir US$ 25 milhões da empresa.

2 Min. Lesezeit

Febre dos peptídeos: entenda o que são e quais os riscos

Gesundheit·16.6.2026KI-Zusammenfassung

Febre dos peptídeos: entenda o que são e quais os riscos

Peptídeos, promovidos como antienvelhecimento e para performance, carecem de comprovação científica e aprovação regulatória no Brasil. Especialistas alertam para riscos de uso sem orientação médica.

7 Min. Lesezeit

Reposição de medicamentos: O que são e como salvam vidas

Gesundheit·16.6.2026KI-Zusammenfassung

Reposição de medicamentos: O que são e como salvam vidas

O reposicionamento de medicamentos, que consiste em encontrar novos usos para fármacos já existentes, tem se mostrado uma estratégia eficaz e econômica para salvar vidas, especialmente em crises de saúde como a da COVID-19. Medicamentos como a dexametasona e o baricitinibe foram reaproveitados para tratar a inflamação em pacientes com coronavírus, salvando milhares de vidas. A Comissão Europeia planeja expandir essa abordagem para a busca de tratamentos contra o câncer. Exemplos históricos incluem o raloxifeno para prevenção de câncer de mama, a talidomida para mieloma múltiplo e o Viagra (sildenafil) para disfunção erétil, originalmente desenvolvido para doenças cardiovasculares. A tendência de reaproveitamento de medicamentos levanta questões sobre seus verdadeiros prós e contras, cujas respostas podem levar anos para serem totalmente compreendidas.

6 Min. Lesezeit

UK Approves First GLP-1 Receptor Agonist Tablet for Weight Management

11.6.2026KI-Zusammenfassung

UK Approves First GLP-1 Receptor Agonist Tablet for Weight Management

The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management. This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.

2 Min. Lesezeit

UK Approves Wegovy Weight-Loss Pill, Expanding Obesity Treatment Options

11.6.2026KI-Zusammenfassung

UK Approves Wegovy Weight-Loss Pill, Expanding Obesity Treatment Options

The UK's MHRA has approved Wegovy, the first GLP-1 receptor agonist tablet for weight loss, making the UK the third country to authorize the pills. This expands treatment options for adults with obesity or overweight with related health conditions.

3 Min. Lesezeit

Wegovy weight-loss pill approved in UK, with prescription needed

11.6.2026KI-Zusammenfassung

Wegovy weight-loss pill approved in UK, with prescription needed

The UK has approved a pill version of the weight-loss drug Wegovy, manufactured by Novo Nordisk. This once-daily tablet, containing semaglutide, mimics a natural hormone to suppress appetite and slow digestion. While available via prescription from pharmacies soon, its NHS availability is pending expert assessment.

2 Min. Lesezeit

Wegovy weight-loss drug pill approved in UK

Gesundheit·11.6.2026KI-Zusammenfassung

Wegovy weight-loss drug pill approved in UK

A pill version of the weight-loss drug Wegovy has been approved in the UK by the MHRA. Manufacturer Novo Nordisk states the once-daily tablet offers convenience over weekly injections and doesn't require refrigeration. Its availability on the NHS is pending expert assessment.

2 Min. Lesezeit

Novo Nordisk Launches Wegovy Weight Loss Pill in UAE, First Market Outside US

Business·3.6.2026KI-Zusammenfassung

Novo Nordisk Launches Wegovy Weight Loss Pill in UAE, First Market Outside US

Novo Nordisk has launched its weight loss pill Wegovy in the United Arab Emirates, marking its first expansion outside the US. The drug, approved for weight management and cardiovascular risk reduction, faces increasing competition in the growing obesity drug market.

2 Min. Lesezeit

17 presos em Salvador em operação contra grupo de roubo a farmácias e tráfico

Crime·3.6.2026KI-Zusammenfassung

17 presos em Salvador em operação contra grupo de roubo a farmácias e tráfico

Dezessete pessoas foram presas em Salvador em uma operação contra um grupo suspeito de roubo a farmácias, tráfico de drogas e armas, e lavagem de dinheiro. A ação também cumpre mandados no Rio de Janeiro e São Paulo, com bloqueio de bens de R$ 12,5 milhões.

2 Min. Lesezeit

Novo Nordisk launches Wegovy weight loss pill in UAE, first market outside US

Business·3.6.2026KI-Zusammenfassung

Novo Nordisk launches Wegovy weight loss pill in UAE, first market outside US

Novo Nordisk has launched its weight loss pill Wegovy in the United Arab Emirates, marking its first expansion outside the U.S. market. The drug's approval by the Emirates Drug Establishment follows recent competition from Eli Lilly in the growing obesity drug sector.

2 Min. Lesezeit

France to Reimburse Obesity Treatments Wegovy and Mounjaro from Mid-June

Gesundheit·3.6.2026KI-Zusammenfassung

France to Reimburse Obesity Treatments Wegovy and Mounjaro from Mid-June

Starting mid-June, France will reimburse 65% of Wegovy and Mounjaro obesity treatments for eligible patients. While patients report effectiveness, high costs and strict eligibility criteria, excluding those with IMC below 35 or 40 without comorbidities, are major concerns.

3 Min. Lesezeit

Medicamento para obesidade chega ao Brasil com preço acessível

2.6.2026KI-Zusammenfassung

Medicamento para obesidade chega ao Brasil com preço acessível

Medicamento para obesidade, semaglutida, chega ao Brasil com preço acessível. Versão nacional da EMS custará R$ 287 por mês na fase inicial, bem abaixo dos R$ 1 mil mensais anteriores.

1 Min. Lesezeit

Traitements contre l'obésité et le surpoids : Wegovy et Mounjaro partiellement remboursés

29.5.2026KI-Zusammenfassung

Traitements contre l'obésité et le surpoids : Wegovy et Mounjaro partiellement remboursés

La France va partiellement rembourser les traitements Wegovy et Mounjaro contre l'obésité et le surpoids, qui permettent une perte de poids jusqu'à 15%.

1 Min. Lesezeit

Retatrutide: The New Obesity Drug Promising 30% Weight Loss

Gesundheit·25.5.2026KI-Zusammenfassung

Retatrutide: The New Obesity Drug Promising 30% Weight Loss

Retatrutide, a new obesity drug from Eli Lilly, has shown a 30% weight loss in trials, surpassing previous drugs like Ozempic. It mimics GLP-1 and other hormones, offering benefits beyond weight loss, including anti-inflammatory effects.

6 Min. Lesezeit